A shortage of dementia specialists and testing capacity could result in significant wait times for new Alzheimer’s treatments as the

Continue readingAlzheimer’s treatment: Patients may wait years for new drugs

The discovery was made by Christopher Martens, assistant professor of kinesiology and applied physiology and director of the Delaware Center for Cognitive Aging Research,

Continue readingAlzheimer’s Breakthrough As Scientists Link NAD+ Supplements to Reduced Biomarkers in the Brain

Israeli scientists gave an artificial molecule they invented to 30 mice suffering from Alzheimer’s — and found that all of

Continue readingIsraeli scientists say they cured mice of Alzheimer’s using newly developed molecule | The Times of Israel

Research into the disease has focused on plaques in the brain. But some scientists think viruses and bacteria play a

Continue readingCould Alzheimer’s be caused by an infection? | Alzheimer’s | The Guardian

The U.S. Food and Drug Administration approved Leqembi, from Japanese drugmaker Eisai, in early January. It’s for patients with mild

Continue readingWhy a new Alzheimer’s drug is having a slow US debut – ABC News

But doctors and health experts are divided on whether it warranted an accelerated FDA approval. While some of them have

Continue readingMedical experts divided on whether 2nd FDA-approved Alzheimer’s drug provides a benefit

The new Alzheimer’s treatment Leqembi will cost an estimated $26,500 per year, according to Eisai, the company that led the

Continue readingAlzheimer’s treatment: Patients would pay up to $26,500 per year for Leqembi

Lecanemab will be marketed as Leqembi, the FDA statement said. It has shown “potential” as an Alzheimer’s disease treatment by

Continue readingAlzheimer’s drug lecanemab receives accelerated FDA approval amid safety concerns | CNN

The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still,

Continue readingFDA Approves, Leqembi, New Treatment for Early Alzheimer’s – The New York Times

Investigators found “atypical collaboration” between the company and the FDA, saying the federal agency went against its own protocols. The

Continue readingFDA controversy over Biogen’s Alzheimer’s drug Aduhelm, explained